200 related articles for article (PubMed ID: 12454280)
1. Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription.
Raspé E; Duez H; Mansén A; Fontaine C; Fiévet C; Fruchart JC; Vennström B; Staels B
J Lipid Res; 2002 Dec; 43(12):2172-9. PubMed ID: 12454280
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha.
Raspé E; Duez H; Gervois P; Fiévet C; Fruchart JC; Besnard S; Mariani J; Tedgui A; Staels B
J Biol Chem; 2001 Jan; 276(4):2865-71. PubMed ID: 11053433
[TBL] [Abstract][Full Text] [Related]
3. Orphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter.
Coste H; Rodríguez JC
J Biol Chem; 2002 Jul; 277(30):27120-9. PubMed ID: 12021280
[TBL] [Abstract][Full Text] [Related]
4. Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element.
Gervois P; Chopin-Delannoy S; Fadel A; Dubois G; Kosykh V; Fruchart JC; Najïb J; Laudet V; Staels B
Mol Endocrinol; 1999 Mar; 13(3):400-9. PubMed ID: 10076997
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha.
Raspè E; Mautino G; Duval C; Fontaine C; Duez H; Barbier O; Monte D; Fruchart J; Fruchart JC; Staels B
J Biol Chem; 2002 Dec; 277(51):49275-81. PubMed ID: 12377782
[TBL] [Abstract][Full Text] [Related]
6. Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver.
Torra IP; Tsibulsky V; Delaunay F; Saladin R; Laudet V; Fruchart JC; Kosykh V; Staels B
Endocrinology; 2000 Oct; 141(10):3799-806. PubMed ID: 11014236
[TBL] [Abstract][Full Text] [Related]
7. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha.
Duez H; van der Veen JN; Duhem C; Pourcet B; Touvier T; Fontaine C; Derudas B; Baugé E; Havinga R; Bloks VW; Wolters H; van der Sluijs FH; Vennström B; Kuipers F; Staels B
Gastroenterology; 2008 Aug; 135(2):689-98. PubMed ID: 18565334
[TBL] [Abstract][Full Text] [Related]
8. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates.
Vu-Dac N; Chopin-Delannoy S; Gervois P; Bonnelye E; Martin G; Fruchart JC; Laudet V; Staels B
J Biol Chem; 1998 Oct; 273(40):25713-20. PubMed ID: 9748239
[TBL] [Abstract][Full Text] [Related]
9. The orphan nuclear receptor Rev-erbalpha recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene.
Yin L; Lazar MA
Mol Endocrinol; 2005 Jun; 19(6):1452-9. PubMed ID: 15761026
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
Mann CJ; Troussard AA; Yen FT; Hannouche N; Najib J; Fruchart JC; Lotteau V; André P; Bihain BE
J Biol Chem; 1997 Dec; 272(50):31348-54. PubMed ID: 9395464
[TBL] [Abstract][Full Text] [Related]
12. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.
Altomonte J; Cong L; Harbaran S; Richter A; Xu J; Meseck M; Dong HH
J Clin Invest; 2004 Nov; 114(10):1493-503. PubMed ID: 15546000
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
Claudel T; Inoue Y; Barbier O; Duran-Sandoval D; Kosykh V; Fruchart J; Fruchart JC; Gonzalez FJ; Staels B
Gastroenterology; 2003 Aug; 125(2):544-55. PubMed ID: 12891557
[TBL] [Abstract][Full Text] [Related]
14. Two initiator-like elements are required for the combined activation of the human apolipoprotein C-III promoter by upstream stimulatory factor and hepatic nuclear factor-4.
Pastier D; Lacorte JM; Chambaz J; Cardot P; Ribeiro A
J Biol Chem; 2002 Apr; 277(17):15199-206. PubMed ID: 11839757
[TBL] [Abstract][Full Text] [Related]
15. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Haubenwallner S; Essenburg AD; Barnett BC; Pape ME; DeMattos RB; Krause BR; Minton LL; Auerbach BJ; Newton RS; Leff T
J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480
[TBL] [Abstract][Full Text] [Related]
16. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
Aalto-Setälä K; Weinstock PH; Bisgaier CL; Wu L; Smith JD; Breslow JL
J Lipid Res; 1996 Aug; 37(8):1802-11. PubMed ID: 8864964
[TBL] [Abstract][Full Text] [Related]
17. The apolipoprotein A-I/C-III/A-IV gene cluster: ApoC-III and ApoA-IV expression is regulated by two common enhancers.
Vergnes L; Taniguchi T; Omori K; Zakin MM; Ochoa A
Biochim Biophys Acta; 1997 Oct; 1348(3):299-310. PubMed ID: 9366246
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice.
Conde-Knape K; Okada K; Ramakrishnan R; Shachter NS
J Lipid Res; 2004 Dec; 45(12):2235-44. PubMed ID: 15342689
[TBL] [Abstract][Full Text] [Related]
19. Binding specificity and modulation of the human ApoCIII promoter activity by heterodimers of ligand-dependent nuclear receptors.
Lavrentiadou SN; Hadzopoulou-Cladaras M; Kardassis D; Zannis VI
Biochemistry; 1999 Jan; 38(3):964-75. PubMed ID: 9893992
[TBL] [Abstract][Full Text] [Related]
20. Role of thyroid hormone in the expression of apolipoprotein A-IV and C-III genes in rat liver.
Lin-Lee YC; Strobl W; Soyal S; Radosavljevic M; Song M; Gotto AM; Patsch W
J Lipid Res; 1993 Feb; 34(2):249-59. PubMed ID: 8429259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
